TY - JOUR
T1 - Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
AU - Venugopal, Sangeetha
AU - Shoukier, Mahran
AU - Konopleva, Marina
AU - Dinardo, Courtney D.
AU - Ravandi, Farhad
AU - Short, Nicholas J.
AU - Andreeff, Michael
AU - Borthakur, Gautam
AU - Daver, Naval
AU - Pemmaraju, Naveen
AU - Sasaki, Koji
AU - Montalban-Bravo, Guillermo
AU - Marx, Kayleigh R.
AU - Pierce, Sherry
AU - Popat, Uday R.
AU - Shpall, Elizabeth J.
AU - Kanagal-Shamanna, Rashmi
AU - Garcia-Manero, Guillermo
AU - Kantarjian, Hagop M.
AU - Kadia, Tapan M.
N1 - Publisher Copyright:
© 2021 American Cancer Society.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Background: Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The benefit of VEN-based therapy in patients who have newly diagnosed AML with mutations in the TP53 gene (TP53mut) over standard therapy is undefined. Methods: In this single-institutional, retrospective analysis, the authors assessed the clinical outcomes of 238 patients with newly diagnosed TP53mut AML and compared the clinical characteristics, response to different therapies, and outcomes of those who received VEN-based (n = 58) and non–VEN-based (n = 180) regimens. Results: Patients who received VEN-based regimens were older (aged >65 years: 81% vs 65%; P =.02) and had higher response rates (complete remission, 43% vs 32%; P =.06) than those who received non–VEN-based regimens. Compared with patients who received non–VEN-based regimens, no difference in overall survival (median, 6.6 vs 5.7 months; P =.4) or relapse-free survival (median, 4.7 vs 3.5 months; P =.43) was observed in those who received VEN-based regimens, regardless of age or intensity of treatment. Conclusions: The addition of VEN to standard treatment regimens did not improve outcomes in younger or older patients who had TP53mut AML. These data highlight the need for novel therapies beyond VEN to improve the outcome of patients with TP53mut AML.
AB - Background: Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The benefit of VEN-based therapy in patients who have newly diagnosed AML with mutations in the TP53 gene (TP53mut) over standard therapy is undefined. Methods: In this single-institutional, retrospective analysis, the authors assessed the clinical outcomes of 238 patients with newly diagnosed TP53mut AML and compared the clinical characteristics, response to different therapies, and outcomes of those who received VEN-based (n = 58) and non–VEN-based (n = 180) regimens. Results: Patients who received VEN-based regimens were older (aged >65 years: 81% vs 65%; P =.02) and had higher response rates (complete remission, 43% vs 32%; P =.06) than those who received non–VEN-based regimens. Compared with patients who received non–VEN-based regimens, no difference in overall survival (median, 6.6 vs 5.7 months; P =.4) or relapse-free survival (median, 4.7 vs 3.5 months; P =.43) was observed in those who received VEN-based regimens, regardless of age or intensity of treatment. Conclusions: The addition of VEN to standard treatment regimens did not improve outcomes in younger or older patients who had TP53mut AML. These data highlight the need for novel therapies beyond VEN to improve the outcome of patients with TP53mut AML.
KW - TP53
KW - acute myeloid leukemia (AML)
KW - hypomethylating agent
KW - venetoclax (VEN)
UR - http://www.scopus.com/inward/record.url?scp=85114190768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114190768&partnerID=8YFLogxK
U2 - 10.1002/cncr.33675
DO - 10.1002/cncr.33675
M3 - Article
C2 - 34182597
AN - SCOPUS:85114190768
SN - 0008-543X
VL - 127
SP - 3541
EP - 3551
JO - Cancer
JF - Cancer
IS - 19
ER -